Qelbree is proven to be safe,* with manageable side effects when taken as directed

*Important: Those taking Qelbree should be monitored for mood or behavior changes. The healthcare provider should also monitor for changes in blood pressure and heart rate.

Safe* and effective treatment for ADHD in children 6-17 years

Summary of these results:

In medical studies, Qelbree was proven to be a safe* and effective treatment for ADHD, with manageable side effects when taken as directed.

In these medical studies, 3% of participants taking Qelbree discontinued the study due to side effects, whereas 1% of those taking the placebo discontinued the study.

See results for Qelbree safety and side effect information from 3 medical studies in over 800 children.

Qelbree is not a controlled substance, and there was no evidence of abuse

Qelbree is unlikely to have any negative interactions with methylphenidate and amphetamine stimulant formulations.

Most common side effects

Side effect	Placebo	Qelbree
Somnolence (drowsiness)^†	4%	16%
Decreased appetite	0.4%	7%
Tiredness	2%	6%
Nausea	3%	5%
Vomiting	2%	4%
Trouble sleeping^‡	1%	4%
Irritability	1%	3%

^†Somnolence: somnolence, lethargy, sedation.

^‡Trouble sleeping: initial insomnia, insomnia, middle insomnia, poor-quality sleep, sleep disorder, terminal insomnia.

3% of participants taking Qelbree discontinued the medical study due to side effects, whereas 1% of those taking the placebo discontinued the medical study.

Talk to your healthcare provider

Get a free, personalized questionnaire to help inform your conversation.

Get your guide

Get the Qelbree Savings Card

Qualified patients may pay as little as $20 per prescription.^§

Get savings card

Frequently asked questions

Find answers to common questions about Qelbree and ADHD.

See FAQs

^§Terms and Conditions apply.

^§Terms and Conditions

This offer is good for most commercially insured and cash-paying patients purchasing Qelbree® and may not be used for any other product. Maximum benefits and quantity of capsules may apply. This offer is not valid for prescriptions purchased under Medicaid, Medicare, or other federal or state programs (such as medical assistance programs). Offer not valid where prohibited by law, taxed, or restricted. It is not transferable and may not be combined with any other offer. The amount of the rebate cannot exceed the patient’s actual out-of-pocket expenses. Offer must be presented along with a valid prescription for Qelbree at the time of purchase. By enrolling into this program you are consenting to the collection and use of certain personal information, including your phone number and/or email address and elements of pharmacy claim information. This information will be collected and used by service providers of Supernus Pharmaceuticals, Inc. (“Supernus”), in order to administer this program. This information is not provided to Supernus directly. If you do not consent, please do not enroll into the program. If you require additional assistance, please call 1-866-398-0833. Supernus reserves the right to rescind, revoke, or amend this offer without notice at any time.

INDICATION

Qelbree^® (viloxazine extended-release capsules) is a prescription medicine used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and children 6 years and older.

IMPORTANT SAFETY INFORMATION
Qelbree may increase suicidal thoughts and actions, in children and adults with ADHD, especially within the first few months of treatment [read more] or when the dose is changed. Tell your doctor if you or your child have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your or your child’s moods, behaviors, thoughts, and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

IMPORTANT SAFETY INFORMATION
Qelbree may increase suicidal thoughts and actions, in children and adults with ADHD, especially within the first few months of treatment or when the dose is changed. [read more] Tell your doctor if you or your child have (or if there is a family history of) suicidal thoughts or actions before starting Qelbree. Monitor your or your child’s moods, behaviors, thoughts, and feelings during treatment with Qelbree. Report any new or sudden changes in these symptoms right away.

You should not take Qelbree if you or your child:
Take a medicine for depression called a monoamine oxidase inhibitor (MAOI) or have stopped taking an MAOI in the past 14 days. Also, you or your child should avoid alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline.

Qelbree can increase blood pressure and heart rate. Your or your child’s doctor will monitor these vital signs.

Qelbree may cause manic episodes in patients with bipolar disorder. Tell your doctor if you or your child show any signs of mania.

Do not drive or operate heavy machinery until you know how Qelbree will affect you or your child. Qelbree may cause you or your child to feel sleepy or tired.

The most common side effects of Qelbree in patients 6 to 17 years are sleepiness, not feeling hungry, feeling tired, nausea, vomiting, trouble sleeping, and irritability, and in adults, insomnia, headache, sleepiness, tiredness, nausea, decreased appetite, dry mouth, and constipation. These are not all the possible side effects of Qelbree.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Medication Guide, including Boxed Warning.

IMPORTANT SAFETY INFORMATION ABOUT QELBREE